Abbey Kaler, MS, APRN, FNP-C, CMSRN, Wins CURE's 2023 Extraordinary Healer Award
Abbey Kaler, MS, APRN, FNP-C, CMSRN, demonstrated extraordinary oncology nursing by being a consistent champion of the patient’s voice.
Nursing Panel Shares Experiences in Managing Toxicities in Renal Cell Carcinoma
Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.
FDA Approves Single-Dose Autoinjector of Biosimilar Pegfilgrastim-cbqv for Febrile Neutropenia
The approval of the Udenyca autoinjector offers easy-to-use design for delivery of the biosimilar pegfilgrastim-cbqv.
Oncology Nursing News Top Stories: February 2023
Each month, Oncology Nursing News® takes a look back at our most popular stories.
Oncology Nursing News Top Stories: January 2023
FDA Approves Zanubrutinib for CLL/SLL
The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.
A Look Back at 2022 FDA Approvals in Oncology
In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.
Oncology Nursing News: Top Stories from 2022
Thank you for reading Oncology Nursing News® in 2022. We look forward to bringing you more news in 2023.
Oncology Nursing News Top Stories: November 2022
In November 2022, HER2-directed therapies made headlines in breast cancer as did innovations to help individuals who are often overlooked in oncology care.
Oncology APPs, Research Nurses Are Uniquely Poised to Tackle irAE Management in Follicular Lymphoma
Because immune-related adverse events can be hard to diagnose, patient education and clear avenues of communication with an oncology care team are critical, according to investigators at the 2022 Pan Pacific Lymphoma Conference.
Investigators Unveil Real-World Experiences on Shared Decision-Making in R/R DLBCL
The ideal model for promoting effective shared decision-making involves tailored caregiver education, adequate time before treatment, and use of multidisciplinary support.
Oncology Nursing News Top Stories: June 2022
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from June 2022.
ONS Annual Congress Focuses on Increasing Nurse Comfort and Patient Understanding in Cancer Care
This year’s congress showcased strategies for communicating sensitive topics, patient experiences with immunotherapy treatments, updates in the utility of
medical cannabis, and more.
A Quick Look at the 2022 AACR Annual Meeting
This year’s conference highlighted advances in natural killer cells, CD39 and KRAS G12C inhibitors, and CAR T-cell therapies.
Complex Cancer Cases: Caring for a Patient With Malignant Bowel Obstruction
Laura Zitella, MS, RN, ACNP-BC, AOCN, reviews a case study where a 52-year-old female patient with metastatic colorectal carcinoma begins experiencing diffuse abdominal pain.
FDA Approves Selinexor for Pretreated Relapsed/Refractory DLBCL
The FDA has approved selinexor as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma, not otherwise specified, who have received ≥2 prior therapies.
Clinical Insights: October 2013
CE lesson worth 1.0 contact hour that is intended for advanced practice nurses, registered nurses, and other healthcare professionals who care for cancer patients.
Clinical Insights: September 2013
ASCO 2013: Building Bridges to Conquer Cancer
CE Activity Worth 1.0 Contact Hour Featuring Highlights From the Year's Largest Oncology Conference and Peer Perspectives From Oncology Nurses.
Clinical Insights: June, 2013
Clinical Insights: May, 2013
Clinical Insights: March/April, 2013
CE lesson worth 1.0 contact hour that is focused on supportive care and research from the 2013 Genitourinary and Gastrointestinal Cancers Symposia.
Clinical Insights: January/February, 2013
CE lesson worth 1.0 contact hour that is focused on research from the 2012 American Society of Hematology Annual Meeting and the San Antonio Breast Cancer Symposium.
Clinical Insights: November/December, 2012
Clinical Insights: October, 2012
Clinical Insights: September, 2012
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive Cranbury, NJ 08512